Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins

Nature Biotechnology

Volumn 22, Issue 10, 2004, Pages 1302-1306

  Fernandez Escamilla, Ana Maria ^a   Rousseau, Frederic ^b   Schymkowitz, Joost ^b   Serrano, Luis ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLOMERATION; DISEASES; PATHOLOGY; POLYPEPTIDES; PROTEINS;

LYSOZYME; PROTEIN AGGREGATION; SHEET FORMATION; STATISTICAL MECHANICS ALGORITHMS;

MUTAGENESIS;

AMYLOID BETA PROTEIN; BETA 2 MICROGLOBULIN; LYSOZYME; PEPTIDE; PREALBUMIN; PRION PROTEIN; PROTEIN;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; MODEL; MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STRUCTURE; STATISTICAL ANALYSIS;

ALGORITHMS; AMINO ACID SUBSTITUTION; BINDING SITES; COMPUTER SIMULATION; DIMERIZATION; MODELS, CHEMICAL; MODELS, MOLECULAR; MODELS, STATISTICAL; MULTIPROTEIN COMPLEXES; MUTAGENESIS, SITE-DIRECTED; MUTATION; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 5044235541     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1012     Document Type: Article

References (27)

1. Chiti, F. et al. Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc. Natl. Acad. Sci. USA 99, 16419-16426 (2002).
2. Chiti, R, Stefani, M., Taddei, N., Ramponi, G. & Dobson, C.M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424, 805-808 (2003).
3. Chiti, F. et al. Kinetic partitioning of protein folding and aggregation. Nat. Struct. Biol. 9, 137-143 (2002).
4. Dobson, C.M. The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond. 6356, 133-145 (2001).
5. Dobson, C.M. Protein-misfolding diseases: getting out of shape. Nature 418, 729-730 (2002).
6. de la Paz, M.L. & Serrano, L. Sequence determinants of amyloid fibril formation. Proc. Natl. Acad. Sci. USA 101, 87-92 (2004).
7. Ramirez-Alvarado, M., Blanco, F.J., Niemann, H. & Serrano, L. Role of beta-turn residues in beta-hairpin formation and stability in designed peptides. J. Mol. Biol. 273, 898-912 (1997).
8. Lopez de la Paz, M., Lacroix, E., Ramirez-Alvarado, M. & Serrano, L. Computer-aided design of beta-sheet peptides. J. Mol. Biol. 312, 229-246 (2001).
9. Vassar, R. et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741 (1999).
10. Caughey, B. & Lansbury, P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
11. Nilsberth, C. et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci, 4, 887-893 (2001).
12. McCutchen, S.L., Lai, Z., Miroy, G.J., Kelly, J.W. & Colon, W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34, 13527-13536 (1995).
13. Pepys, M.B. et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362, 553-557 (1993).
14. Almeida, M.R., Alves, I.L.Terazaki, H., Ando, Y. & Saraiva, M.J. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem. Biophys. Res. Commun. 270, 1024-1028 (2000).
15. Hammarstrom, P., Schneider, F. & Kelly, J.W. Trans-suppression of misfolding in an amyloid disease. Science 293, 2459-2462 (2001).
16. Quintas, A., Saraiva, M.J. & Brito, R.M. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett 418, 297-300 (1997).
17. Shnyrov, V.L. et al. Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophys. Chem. 88, 61-67 (2000).
18. Canet, D. et al. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat. Struct. Biol. 9, 308-315 (2002).
19. Morozova-Roche, L.A. et al. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J. Struct. Biol. 130, 339-351 (2000).
20. Chamberlain, A.K., Receveur, V., Spencer, A., Redfield, C. & Dobson, C.M. Characterization of the structure and dynamics of amyloidogenic variants of human lysozyme by NMR spectroscopy. Protein Sci. 10, 2525-2530 (2001).
21. Booth, D.R. et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793 (1997).
22. Guerois, R., Nielsen, J.E. & Serrano, L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 320, 369-387 (2002).
23. Lacroix, E., Viguera, A.R. & Serrano, L. Elucidating the folding problem of alpha-helices: Local motifs, long-range electrostatics, ionic-strength dependence and prediction of NMR parameters. J. Mol. Biol. 284, 173-191 (1998).
24. Blanco, F.J. & Serrano, L. Folding of protein G B1 domain studied by the conformational characterization of fragments comprising its secondary structure elements. Eur. J. Biochem. 230, 634-649 (1995).
25. Luo, P. & Baldwin, R.L. Mechanism of helix induction by trifluoroethanol: a framework for extrapolating the helix-forming properties of peptides from trifluoroethanol/water mixtures back to water. Biochemistry 36, 8413-8421 (1997).
26. Naiki, H. & Nakakuki, K. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab. Invest 74, 374-383 (1996).
27. Mathews, B.W. Comparison of predicted and observed secondary structure of t4 phage lysozyme. Biochim. Biophys. Acta 405, 442-451 (1975).